These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32690647)

  • 41. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.
    Solans BP; Imperial MZ; Olugbosi M; Savic RM
    Clin Infect Dis; 2023 Jun; 76(11):1903-1910. PubMed ID: 36804834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
    J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
    Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
    BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
    Lyons MA
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0089822. PubMed ID: 36377952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients.
    van de Berg SEJ; Pelzer PT; van der Land AJ; Abdrakhmanova E; Ozi AM; Arias M; Cook-Scalise S; Dravniece G; Gebhard A; Juneja S; Handayani R; Kappel D; Kimerling M; Koppelaar I; Malhotra S; Myrzaliev B; Nsa B; Sugiharto J; Engel N; Mulder C; van den Hof S
    BMC Public Health; 2021 Jul; 21(1):1404. PubMed ID: 34271884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
    Dheda K; Gumbo T; Maartens G; Dooley KE; Murray M; Furin J; Nardell EA; Warren RM;
    Lancet Respir Med; 2019 Sep; 7(9):820-826. PubMed ID: 31486393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.
    Timm J; Bateson A; Solanki P; Paleckyte A; Witney AA; Rofael SAD; Fabiane S; Olugbosi M; McHugh TD; Sun E
    PLOS Glob Public Health; 2023; 3(10):e0002283. PubMed ID: 37851685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
    de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pretomanid: The latest USFDA-approved anti-tuberculosis drug.
    Deb U; Biswas S
    Indian J Tuberc; 2021 Apr; 68(2):287-291. PubMed ID: 33845969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.
    Kaushik A; Ammerman NC; Tyagi S; Saini V; Vervoort I; Lachau-Durand S; Nuermberger E; Andries K
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evolving strategies for dose optimization of linezolid for treatment of tuberculosis.
    Nuermberger E
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):48-51. PubMed ID: 28240573
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pretomanid: First Approval.
    Keam SJ
    Drugs; 2019 Nov; 79(16):1797-1803. PubMed ID: 31583606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
    J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)].
    Otto-Knapp R; Bauer T; Brinkmann F; Feiterna-Sperling C; Friesen I; Geerdes-Fenge H; Hartmann P; Häcker B; Hauer B; Haas W; Heyckendorf J; Kuhns M; Lange C; Maurer FP; Nienhaus A; Priwitzer M; Richter E; Salzer HJF; Schoch O; Schönfeld N; Schaberg T
    Pneumologie; 2024 Jan; 78(1):35-46. PubMed ID: 37931778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
    Esmail A; Oelofse S; Lombard C; Perumal R; Mbuthini L; Goolam Mahomed A; Variava E; Black J; Oluboyo P; Gwentshu N; Ngam E; Ackerman T; Marais L; Mottay L; Meier S; Pooran A; Tomasicchio M; Te Riele J; Derendinger B; Ndjeka N; Maartens G; Warren R; Martinson N; Dheda K
    Am J Respir Crit Care Med; 2022 May; 205(10):1214-1227. PubMed ID: 35175905
    [No Abstract]   [Full Text] [Related]  

  • 59. Bioisosteric modification of Linezolid identified the potential
    Girase R; Ahmad I; Patel H
    J Biomol Struct Dyn; 2024; 42(4):2111-2126. PubMed ID: 37097976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report.
    De Vito A; Fiore V; Urru V; Bozzi E; Geremia N; Princic E; Canu D; Molicotti P; Are R; Babudieri S; Madeddu G
    Braz J Infect Dis; 2022; 26(5):102701. PubMed ID: 36096158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.